These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

276 related articles for article (PubMed ID: 11827924)

  • 1. Quality of life in the antiarrhythmics versus implantable defibrillators trial: impact of therapy and influence of adverse symptoms and defibrillator shocks.
    Schron EB; Exner DV; Yao Q; Jenkins LS; Steinberg JS; Cook JR; Kutalek SP; Friedman PL; Bubien RS; Page RL; Powell J
    Circulation; 2002 Feb; 105(5):589-94. PubMed ID: 11827924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Causes of death in the Antiarrhythmics Versus Implantable Defibrillators (AVID) Trial.
    J Am Coll Cardiol; 1999 Nov; 34(5):1552-9. PubMed ID: 10551706
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiarrhythmic drug use in the implantable defibrillator arm of the Antiarrhythmics Versus Implantable Defibrillators (AVID) Study.
    Steinberg JS; Martins J; Sadanandan S; Goldner B; Menchavez E; Domanski M; Russo A; Tullo N; Hallstrom A;
    Am Heart J; 2001 Sep; 142(3):520-9. PubMed ID: 11526368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival of antiarrhythmic or implantable cardioverter defibrillator treated patients with varying degrees of left ventricular dysfunction who survived malignant ventricular arrhythmias.
    Domanski MJ; Epstein A; Hallstrom A; Saksena S; Zipes DP
    J Cardiovasc Electrophysiol; 2002 Jun; 13(6):580-3. PubMed ID: 12108501
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Partner quality of life in the antiarrhythmics versus implantable defibrillators trial.
    Jenkins LS; Powell JL; Schron EB; McBurnie MA; Bosworth-Farrell S; Moore R; Exner DV;
    J Cardiovasc Nurs; 2007; 22(6):472-9. PubMed ID: 18090188
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Concerns about the implantable cardioverter defibrillator: a determinant of anxiety and depressive symptoms independent of experienced shocks.
    Pedersen SS; van Domburg RT; Theuns DA; Jordaens L; Erdman RA
    Am Heart J; 2005 Apr; 149(4):664-9. PubMed ID: 15990750
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Implantable Cardioverter Defibrillator Shocks and Psychological Distress: Examining the Mediating Roles of Implantable Cardioverter Defibrillator-Related Concerns and Perceived Control.
    Lee KS; Hammash MH; Kim JH; Kang KW; Miller J; McEvedy SM; Hwang SY; Moser DK
    J Cardiovasc Nurs; 2020; 35(1):66-73. PubMed ID: 31441803
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Do baseline characteristics accurately discriminate between patients likely versus unlikely to benefit from implantable defibrillator therapy? Evaluation of the Canadian implantable defibrillator study implantable cardioverter defibrillatory efficacy score in the antiarrhythmics versus implantable defibrillators trial.
    Exner DV; Sheldon RS; Pinski SL; Kron J; Hallstrom A
    Am Heart J; 2001 Jan; 141(1):99-104. PubMed ID: 11136493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ranolazine reduces ventricular tachycardia burden and ICD shocks in patients with drug-refractory ICD shocks.
    Bunch TJ; Mahapatra S; Murdock D; Molden J; Weiss JP; May HT; Bair TL; Mader KM; Crandall BG; Day JD; Osborn JS; Muhlestein JB; Lappe DL; Anderson JL
    Pacing Clin Electrophysiol; 2011 Dec; 34(12):1600-6. PubMed ID: 21895727
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of the implantable cardioverter-defibrillator versus antiarrhythmic drugs in survivors of serious ventricular tachyarrhythmias: results of the Antiarrhythmics Versus Implantable Defibrillators (AVID) economic analysis substudy.
    Larsen G; Hallstrom A; McAnulty J; Pinski S; Olarte A; Sullivan S; Brodsky M; Powell J; Marchant C; Jennings C; Akiyama T;
    Circulation; 2002 Apr; 105(17):2049-57. PubMed ID: 11980684
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact of Chronic Total Coronary Occlusion on Recurrence of Ventricular Arrhythmias in Ischemic Secondary Prevention Implantable Cardioverter-Defibrillator Recipients (VACTO Secondary Study): Insights From Coronary Angiogram and Electrogram Analysis.
    Nombela-Franco L; Iannaccone M; Anguera I; Amat-Santos IJ; Sanchez-Garcia M; Bautista D; Calvelo MN; Di Marco A; Moretti C; Pozzi R; Scaglione M; Cañadas V; Sandin-Fuentes M; Arenal A; Bagur R; Perez-Castellano N; Fernandez-Perez C; Gaita F; Macaya C; Escaned J; Fernández-Lozano I
    JACC Cardiovasc Interv; 2017 May; 10(9):879-888. PubMed ID: 28473110
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A; Husser D; Cannom DS
    Am J Cardiovasc Drugs; 2005; 5(6):371-8. PubMed ID: 16259525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Renal disease and cardiac mortality in survivors of sudden cardiac death.
    Rathod A; Badheka A; Kizilbash M; Manickam P; Mohamad T; Bhat S; Afonso L; Jacob S
    Acta Cardiol; 2010 Jun; 65(3):323-8. PubMed ID: 20666271
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Implantable cardioverter defibrillator therapy and the need for concomitant antiarrhythmic drugs.
    Singh S; Murawski MM
    J Cardiovasc Pharmacol Ther; 2007 Sep; 12(3):175-80. PubMed ID: 17875944
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender disparities in quality of life and psychological disturbance in patients with implantable cardioverter-defibrillators.
    Rahmawati A; Chishaki A; Sawatari H; Tsuchihashi-Makaya M; Ohtsuka Y; Nakai M; Miyazono M; Hashiguchi N; Sakurada H; Takemoto M; Mukai Y; Inoue S; Sunagawa K; Chishaki H
    Circ J; 2013; 77(5):1158-65. PubMed ID: 23337265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quality of life in patients with implantable cardioverter-defibrillator: systematic review of randomized controlled trials.
    da Silva KR; Costa R; Rodrigues CG; Schasechter A; Nobre MC; Passman R; Mark DB
    Eur J Cardiovasc Nurs; 2018 Mar; 17(3):196-206. PubMed ID: 29067836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Defibrillator shocks and their effect on objective and subjective patient outcomes: Results of the PainFree SST clinical trial.
    Sears SF; Rosman L; Sasaki S; Kondo Y; Sterns LD; Schloss EJ; Kurita T; Meijer A; Raijmakers J; Gerritse B; Auricchio A
    Heart Rhythm; 2018 May; 15(5):734-740. PubMed ID: 29277687
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of programming strategies aimed at reducing nonessential implantable cardioverter defibrillator therapies on mortality: a systematic review and meta-analysis.
    Tan VH; Wilton SB; Kuriachan V; Sumner GL; Exner DV
    Circ Arrhythm Electrophysiol; 2014 Feb; 7(1):164-70. PubMed ID: 24446023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incidence of shock and quality of life in young patients with implantable cardioverter-defibrillator.
    Costa R; Silva KR; Mendonça RC; Nishioka SA; Siqueira Sde F; Tamaki WT; Crevelari ES; Moreira LF; Filho MM
    Arq Bras Cardiol; 2007 Mar; 88(3):258-64. PubMed ID: 17533465
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of antiarrhythmic drugs in patients with implantable cardioverter defibrillators.
    Van Herendael H; Pinter A; Ahmad K; Korley V; Mangat I; Dorian P
    Europace; 2010 May; 12(5):618-25. PubMed ID: 20304841
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.